Personalized immune cells tested to fight five tough cancers
NCT ID NCT06626256
Summary
This early-stage study aimed to test the safety and initial effectiveness of a personalized cell therapy called STIL101 for patients with advanced cancers that have spread or cannot be removed by surgery. The therapy involved growing a patient's own immune cells from a tumor sample in a lab and then infusing them back into the patient to attack the cancer. The study was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.